Ascletis Pharma’s ASC30 Shows Positive Results in US Phase Ib Obesity Study
China-based Ascletis Pharma Inc. (HKG: 1672) announced positive interim results from a Phase Ib study...
Abbisko Therapeutics Secures $85M from Merck for Pimicotinib Global Rights
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that its German partner Merck KGaA...
Chia Tai Tianqing Launches NPP for Urgent Cancer Treatment in Hong Kong
China-based Chia Tai Tianqing Pharmaceutical has entered into a Named Patient Program (NPP) collaboration with...
Innovent Biologics’ IBI363 Granted Breakthrough Therapy Designation for Melanoma
China-based Innovent Biologics, Inc. (HKG: 1801) announced that it has received breakthrough therapy designation (BTD)...
NHC Data Reveals Digital Leap for Class 3 Hospitals Amid Drug Cost Crackdown
China’s 2,168 Class 3 public hospitals demonstrated enhanced fiscal discipline in 2023, with medical services...
Hengrui’s HRS-5965 Granted Breakthrough Therapy Designation for IgA Nephropathy
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received breakthrough therapy...
Sanofi’s Dupixent Approved in Japan for Chronic Obstructive Pulmonary Disease
Sanofi (EPA: SAN, NASDAQ: SNY) announced that it has received approval from Japan’s Ministry of...
Pacific Shuanglin Bio-pharmacy Partners with XtalPi for Blood Product Innovation
China-based Pacific Shuanglin Bio-pharmacy Co., Ltd (SHE: 000403) has formed a strategic partnership with Shenzhen-based...
Novartis’ Pluvicto Gains Expanded FDA Approval for Prostate Cancer Treatment
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that it has received expanded indication approval from...
EMA’s CHMP Issues Negative Opinion on Lilly’s Kisunla for Alzheimer’s
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
China’s IAC Drafts Commercial Health Insurance Drug List A-Series to Bridge NRDL Coverage Gaps
The Insurance Association of China (IAC) has unveiled its inaugural draft for the Commercial Health...
China Scraps Outpatient Prepayment in Public Hospitals by 2025: Healthcare Reform Shifts Financial Burden
The National Health Commission (NHC) will eliminate outpatient prepayment requirements across public medical institutions by...
uBriGene Appoints Dr. Joy Zhou to Lead Cell Therapy Development
China-based advanced therapy medicinal product (ATMP) contract development and manufacturing organization (CDMO) uBriGene Biosciences announced...
BMS’s Opdivo/Yervoy Combo Approved by NMPA for First-Line HCC Treatment
Bristol-Myers Squibb (BMS, NYSE: BMY) announced that it has received approval from China’s National Medical...
Roche’s Ocrevus Approved by China’s NMPA for Multiple Sclerosis Treatment
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that it has received marketing approval...
Shanghai Bio-heart Launches SAKURA-SCB Study for Drug-Coated Balloon in Japan
China-based Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) announced the first patient enrollment for...
AstraZeneca’s Imfinzi Approved by FDA for Bladder Cancer Treatment
The US Food and Drug Administration (FDA) has approved AstraZeneca’s (NASDAQ: AZN) PD-L1 inhibitor Imfinzi...
MicroPort Endovascular Reports 1.61% Revenue Growth in 2024 with Strong Profit Increase
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) released its 2024 financial report, showing a...
Luye Pharma Group Reports 2024 Revenue Dip Despite Growth in Product Sales
China-based Luye Pharma Group (HKG: 2186) announced its 2024 financial performance, recording RMB 6.061 billion...
Hengrui Pharmaceuticals Reports 22.63% Revenue Growth in 2024 with Strong Innovative Drug Sales
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) released its 2024 financial report, recording RMB...